secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2026-10-05T12:08:08+00:00
Accession:  0001193125-26-413177
Event type: regulatory
Sentiment:  neutral
Materiality: 0.45
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Benitec: FDA requests more BB-301 data; pivotal design due 1Q 2027, enrollment mid-2027
--------------------------------------------------------------------------------

- FDA formal feedback after a 3Q 2026 Type C meeting asked Benitec for additional available data, including results from the company-sponsored OPMD Natural History Study.
- Benitec expects to confirm the final design of the open-label, single-arm BB-301 pivotal study in 1Q 2027; patient enrollment planned to begin mid-2027, with timelines 'on track'.
- Interim Phase 1b/2a data to be presented as a late-breaking poster at ESGCT in Hamburg, Oct 27-30, 2026: 12-month follow-up for all six Cohort 1 patients, interim data for three Cohort 2 patients.
- CEO Jerel A. Banks said the requested data will go to the FDA 'in the coming weeks'; goal is BB-301 as the first approved disease-modifying therapy for OPMD-related dysphagia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312526413177/0001193125-26-413177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312526413177/bntc-20261005.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-413177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer